Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 198

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

Open access
Morgan, Gareth J., Davies, Faith E., Gregory, Walter M., Russell, Nigel H., Bell, Sue E., Szubert, Alexander J., Coy, Nuria Navarro, Cook, Gordon, Feyler, Sylvia, Byrne, Jenny L., Roddie, Huw, Rudin, Claudius, Drayson, Mark T., Owen, Roger G., Ross, Fiona M., Jackson, Graham H., Child, J. Anthony, for the NCRI Haematological Oncology Study Group · 2011 · Blood

Abstract

As part of the randomized MRC Myeloma IX trial, we compared an attenuated regimen of cyclophosphamide, thalidomide, and dexamethasone (CTDa; n = 426) with melphalan and prednisolone (MP; n = 423) in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation. The primary endpoints were overall response rate, progression-free survival, and overall survival (OS). The overall response rate was significantly higher with CTDa than MP (63.8% vs 32.6%; P < .0001), primarily because of increases in the rate of complete responses (13.1% vs 2.4%) and very good partial responses (16.9% vs 1.7%). Progression-free survival and OS were similar between groups. In this population, OS correlated with the depth of response (P < .0001) and favorable interphase fluorescence in situ hybridization profile (P < .001). CTDa was associated with higher rates of thromboembolic events, constipation, infection, and neuropathy than MP. In elderly patients with newly diagnosed multiple myeloma (median age, 73 years), CTDa produced higher response rates than MP but was not associated with improved survival outcomes. We highlight the importance of cytogenetic profiling at diagnosis and effective management of adverse events. This trial was registered at International Standard Randomized Controlled Trials Number as #68454111.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-02-338665

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 198

Metadata

Authors
Morgan, G. J., Davies, F. E., Gregory, W. M., Russell, N. H., Bell, S. E., Szubert, A. J., Coy, N. N., Cook, G., Feyler, S., Byrne, J. L., Roddie, H., Rudin, C., Drayson, M. T., Owen, R. G., Ross, F. M., Jackson, G. H., Child, J. A., & for the NCRI Haematological Oncology Study Group
Venue
Blood
Published
2011-08-04
Volume
118
Issue
5
Pages
1231-1238
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2074734350
Cited by
198
References
1
FWCI
15.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. https://app.cochat.ai/papers/10.1182/blood-2011-02-338665
The paper
Morgan, G. J., Davies, F. E., Gregory, W. M., Russell, N. H., Bell, S. E., Szubert, A. J., Coy, N. N., Cook, G., Feyler, S., Byrne, J. L., Roddie, H., Rudin, C., Drayson, M. T., Owen, R. G., Ross, F. M., Jackson, G. H., Child, J. A., & for the NCRI Haematological Oncology Study Group. (2011). Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. https://doi.org/10.1182/blood-2011-02-338665

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.